Skip to Content
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 09/21/23

Hawai‘i Minority Health and Cancer Disparities SPORE

University of Hawai‘i

Principal Investigator(s):

Loic Le Marchand, MD, PhD
Loic Le Marchand, MD, PhD

Jeffrey Berenberg, MD, MACP
Jeffrey Berenberg, MD, MACP

Principal Investigator(s) Contact Information

Loic Le Marchand, MD, PhD
Associate Director, Community Outreach and Engagement
Associate Director, Population Sciences
Professor (Researcher), Population Sciences in the Pacific Program (Cancer Epidemiology)
University of Hawai‘i Cancer Center
701 Ilalo Street
Room 530
Honolulu, Hawaii, 98613
(808) 348-2029

Jeffrey Berenberg, MD, MACP
Professor, Translational and Clinical Research
University of Hawaii
Medical Director and Core Clinical Member, Translational and Clinical Research
University of Hawaii Cancer Center
701 Ilalo Street
Honolulu, Hawaii, 98613
(808) 356-5745

Overview

At the root of health disparities is the diversity that exists in the biological, behavioral, sociocultural, and environmental characteristics of individuals and populations. Hawai‘i offers exceptional opportunities for minority health research due to its uniquely diverse population with varying cancer burdens and its high-quality health care and cancer registration. The University of Hawai‘i Cancer Center (UHCC) has a successful track record of leveraging Hawai‘i’s multiethnic population to study racial/ethnic differences in cancer risk and outcomes. The goal of this planning grant is to establish a SPORE program to conduct translational research focusing on Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPI), the fastest growing US minority, to address cancers of particular relevance to these populations.

Project 1 addresses the excess lung cancer burden experienced by Native Hawaiians by developing a risk-based and culturally informed lung cancer screening strategy, and investigates the mutation, methylation, and transcriptomic profiles of lung tumors in Native Hawaiians compared to Whites.

Project 2 addresses the very high breast cancer burden of Native Hawaiians and the sharply rising rates in Asian Americans by testing the adequacy of current radiomic risk prediction algorithms for predicting breast cancer in these populations and by investigating related molecular and histopathologic features of the breast tumor microenvironment which may be related to visceral adiposity and have prognostic significance.

The SPORE is supported by: 1) an Administrative Core with strategic planning, scientific and community advisory, and evaluation components; 2) an Outreach and Recruitment Core facilitating studies among minorities; 3) a centralized biorepository of paired fresh-frozen tumor and blood samples, as well as archival tumor blocks (Pathology & Biospecimen Core); 4) a Biostatistics & Bioinformatics Core; 5) a Developmental Research Program to fund innovative pilot studies and a Career Enhancement Program to support promising investigators new to translational research; and 6) new collaborations, with other institutions for the further translation of our findings. The successful completion of this program will significantly advance our ability to reduce the high cancer burden in AANHPI and to conduct innovative translational minority health research that will benefit Hawaii, the Pacific region and the rest of the US.

PROJECT 1: Mitigating Lung Cancer Disparities in Native Hawaiians — A Population-Based Approach to Evaluate Prevention Barriers and Lung Tumor Biology

Project Co-Leaders:
Jeffrey Berenberg, MD (Clinical)
S. Lani Park, PhD (Applied)
Lenora Loo, PhD (Basic)

We have shown in the Multiethnic Cohort that Native Hawaiians have a markedly higher risk of lung cancer and poorer survival from the disease compared to (non-Hispanic) Whites, even after accounting for smoking history and other factors. This excess risk was observed for all cell types, the poorer survival with early stage only. While the high risk in African Americans and low risk in Japanese Americans can be explained by higher and lower smoking intensity (carcinogens dose per cigarette), due to smoking behavior and lower nicotine metabolism, respectively, reasons for the risk excess in Native Hawaiians remain unknown. Lung cancer screening using low-dose Computed Tomography (LDCT) among smokers aged 50-80 years who have a 20+ pack-year history, or have quit within the past 15 years, has been shown to decrease mortality. However, the state of Hawaii ranks last in the proportion of lung cancers diagnosed at an early stage (19% vs. 24% nationally), with less than 3% of high-risk smokers undergoing LDCT screening (national average: 6%). Studies have suggested that the use of risk-based prediction models may be more effective than the U.S. Preventive Services Task Force (USPSTF) criteria at identifying high-risk smokers for lung cancer screening. However, both the USPSTF guidelines and these risk models were derived from mostly European-descent populations. There may be distinct biological processes that contribute to the excess risk and poor outcome for Native Hawaiians. For example, we observed differences in epigenetic patterns in blood DNA associated with smoking dose in Native Hawaiians compared to other groups, with the differential methylation occurring in cancer-related genes. Project 1 is conducting a multilevel study to:

Specific Aims:

Aim 1: Identify the individual and provider-based barriers for lung cancer screening to develop an intervention strategy to be disseminated with the Hawaii Department of Health.

Aim 2: Better identify those at greatest risk of developing lung cancer by computing a Native Hawaiian-specific risk prediction model.

Aim 3: Characterize the tumor pathobiology associated with the poor survival of Native Hawaiian lung cancer patients. Study findings will provide critical information along the continuum of lung cancer healthcare for a high-risk minority population.

PROJECT 2: Inter-Relationships and Prognostic Significance of Breast Cancer Radiomic Risk Features, Tissue Microenvironment and Adiposity

Projects Co-Leaders:
John Shepherd, PhD (Applied)
Jami Fukui, MD (Clinical)
Lenora Loo, PhD (Basic)
Brenda Hernandez, PhD (Applied)

The risk of breast cancer among U.S. women dramatically differs across racial and ethnic populations. Nonetheless, Asian Americans, Native Hawaiians and Pacific Islanders (AANHPI) have been historically underrepresented in breast cancer research. Consequently, there are major gaps in understanding disparities in these populations, including high incidence and mortality among Native Hawaiians and a steadily rising incidence with comparatively favorable outcomes among Japanese Americans. Obesity and breast density, established breast cancer risk factors, vary widely across AANHPI women and have direct implications for mammographic screening and primary prevention. Our research to date provides strong evidence that body fat distribution, specifically, visceral adipose tissue (VAT), is an important predictor of breast cancer risk. The influence of adiposity on breast density and other aspects of breast architecture that can be discerned through mammographic screening (e.g., radiomic features) is not well understood. Our long-term goal is to elucidate the breast cancer disparities seen in understudied minority AANHPI subgroups that can be translated to improved prevention, early detection, and therapeutic strategies. Our central hypothesis is that established radiomic risk features have unique associations with breast cancer incidence in AANHPI subgroups and that they are correlated with tissue biomarkers of risk and prognosis and with obesity, especially VAT. Study resources include the statewide Hawai‘i Pacific Islands Mammography Registry, the Hawai‘i Tumor Registry and its Residual Tissue Repository, and the Multiethnic Cohort Study (MEC). Our aims are to:

Specific Aims:

Aim 1: Characterize the relationships of established breast imaging radiomic risk features with tissue protein biomarker expression profiles reflecting the tissue microenvironment and breast cancer prognosis and with disease-specific survival.

Aim2: Characterize the joint relationships of breast radiomic risk features and measures of adiposity, including VAT, with post-menopausal breast cancer risk among MEC participants.

Aim 3: Calibrate commonly used risk prediction models for breast cancer by including established breast radiomic (AI and machine learning) risk features from 2D and 3D mammography in AAPHI and White women overall and by estrogen/ progesterone receptor and HER-2 status. Project 2 will improve risk and prognosis model accuracy and better identify high risk women for further assessment or tailored therapy.

Administrative Core

Core Co-Directors:
Loïc Le Marchand, MD, PhD
Jeffrey Berenberg, MD, MACP

The purpose of the Administrative Core is to provide the leadership and administrative management for the proposed multidisciplinary P20 SPORE aimed at capitalizing on the infrastructure at the University of Hawaii Cancer Center (UHCC) and the racial/ethnic diversity of its catchment area to conduct translational research addressing the racial/ethnic differences in cancer risks and outcomes that exist in Hawaii and the Pacific. The Administrative Core builds upon a number of UHCC resources, both administrative and scientific, to foster the implementation and coordination of the research in this SPORE. This Core will also closely coordinate the P20 resource-building and career-development activities with those implemented by UHCC, so greater efficiency is achieved at the institutional level. Thus, this Core serves major administrative and integrative functions for the SPORE.

Specific Aims:

Aim 1: To provide the overall scientific and administrative coordination and joint leadership for the P50 grant. This function ensures that research progresses effectively, investigators engage in optimal intellectual interactions, and effective career enhancement activities take place.

Aim 2: To coordinate and integrate the P50 activities with those of UHCC.

Aim 3: To plan and evaluate current and future translational cancer disparities research as part of the P50 grant.

Pathology and Biospecimen Core

Core Co-Directors :
Brenda Hernandez, PhD
Owen Chan, MD, PhD

The lack of research specimens from racial and ethnic minority populations in the U.S. remains a barrier to understanding racial/ethnic differences in cancer development, progression, and outcomes. In particular, the paucity of clinical biospecimens from understudied populations, including Native Hawaiians, other Pacific Islanders, and Asian Americans (AANHPI) has limited the ability to address critical disparities in cancer risk and outcomes affecting these U.S. communities. The Pathology and Biospecimen Core integrates and augments existing and new biospecimen resources with respect to their acquisition, processing, tracking, storage, and distribution and will support Project 1 (lung cancer), Project 2 (breast cancer), Career Enhancement Program (CEP) and Developmental Research Program (DRP) projects, as well as other UHCC investigations with the goal of developing a robust infrastructure to address differences in cancer risk and outcomes in AANHPI ethnic minority populations. Aim 1 focuses on developing a repository of paired fresh frozen tumor tissue and blood specimens from multiethnic cancer cases diagnosed in the state of Hawaii with cancers of the lung, liver, breast, colorectum, endometrium, pancreas, and stomach. Potential cases will be identified via rapid reporting from medical facilities statewide through the NCI SEER Hawaii Tumor Registry. Aim 2 is to provide biospecimens from new and existing resources in support of Projects 1 and 2, CEP and DRP projects, and future cancer research projects.

Specific Aims:

Aim 1: To develop a multiethnic biospecimen repository of paired fresh frozen tumor tissue and blood specimens from Hawai‘i residents diagnosed with cancers of the liver, lung, breast, colorectum, endometrium, pancreas, and stomach. Individuals — including Native Hawaiians, Micronesians, Samoans, Filipinos, Japanese, other Asians, and non-Hispanic Whites — will be identified at medical facilities of the statewide Hawai‘i Cancer Consortium through rapid case ascertainment by the NCI SEER Hawai‘i Tumor Registry in order to ensure population representation.

Aim 2: To provide biospecimens from new and existing resources in support of Project 1, Project 2, Project 3, Career Enhancement Program (CEP) and Developmental Research Program (DRP) projects, and future cancer minority health and cancer disparities research in Hawai‘i.

Biostatistics and Bioinformatics Core

Core Co-Directors:
Lynne Wilkens, Dr.PH
Youping Deng, PhD

The goal of the Biostatistics and Bioinformatics Core (BBC) is to provide support to the SPORE projects, other cores, as well as the researchers funded through the Developmental Research Program or Career Enhancement Program in all aspects of study design and data management, processing, integration and analysis.

Specific Aims:

Aim 1: To provide support for data management and integration for the projects, while ensuring data quality and security processes are incorporated.

Aim 2: To develop and execute study design and analysis plans for each of the research projects, in conjunction with Project Leaders; and 3) to facilitate data sharing among SPORE researchers and with the research community.

Outreach and Recruitment Core

Core Director:
Kevin Cassel, DPH

The Outreach and Recruitment Core (ORC) plays an integral role in the proposed research to achieve the overarching goal of maximizing the translational impact of our ethnic disparities research in our catchment area [Hawaii and the US-Affiliated Pacific Islands (USAPIs)]. The function of the Core is to perform community outreach and recruitment activities specifically in support of the projects and, in the process, engage our minority populations broadly to increase their awareness of cancer disparities and obtain their input on our research and dissemination.

Specific Aims:

Aim 1a: Is to establish the SPORE’s Community Advisory Board (CAB) to increase public and healthcare provider awareness of racial/ethnic and geographic cancer disparities among AANHPI in Hawai‘i and elicit community input, participation, and knowledge related to SPORE research projects addressing specific cancers.

Aim 1b: Is to increase awareness of specific cancer disparities among healthcare providers and patient community organizations and engage their input and participation in SPORE projects.

Aim 2: Is to: a) conduct provider and community key-informant interviews, and pilot message testing for Project 1; b) disseminate the risk assessment research and study findings to stakeholders for Project 2; and c) support the pilot work funded by the Developmental Research Program and Career Enhancement Program. Bidirectional engagement with the community throughout the research process is essential for translational research in minorities to be successful.

Developmental Research Program

Program Director:
Gertraud Maskarinec, MD, PhD

The Developmental Research Program (DRP) will draw upon areas of unique opportunity at UHCC to foster minority health research that will improve our biological understanding of ethnic/racial differences in cancer risk and outcomes in our catchment area and translate our findings into therapeutic, behavioral, and diagnostic clinical trials and interventions that address these challenges. The DRP is a central element of the P20 for developing new translational research projects in minority health that will nurture new lines of investigation, research innovation, and collaboration. The funded pilot projects will provide important preliminary data for future large research project applications and support their feasibility and impact. Therefore, the DRP is an engine for innovation in translational minority health research at UHCC. The goal of the DRP is to identify and fund new research projects and collaborations that address minority health issues in UHCC’s catchment area. In support of this goal, the DRP coordinates pilot funding requests, reviews, and award activities and identifies areas of unique opportunity and potential collaborations. These projects will form the basis for the continued success of this minority health SPORE and expand its impact by fostering the development of new research topics.

Specific Aims:

Aim 1: Coordination of Pilot Funding activities.

Aim 2: Identify Areas of Unique Opportunity for Pilot Projects and collaborations, and facilitate these.

Career Enhancement Program

Program Director:
Gertraud Maskarinec, MD, PhD

The goal of the Career Enhancement Program (CEP) is to identify and mentor investigators who show promise for independent research careers in translational research in minority health and correcting ethnic/racial disparities in cancer. The CEP provides funding and mentoring to junior faculty who are developing an independent research program and provides support to established investigators to greatly enhance or refocus their careers on minority health research. In service of this goal, the CEP: 1) coordinates identification of promising new research in disparities research from junior faculty and established investigators looking to refocus their research in this area; 2) provides training, career development and mentoring to awardees in minority health research; 3) monitors the progress of CEP awardees as they develop independent careers and/or new research programs in minority health, and assesses the effectiveness of the CEP approach.

Specific Aims:

Aim 1: Coordinate identification and implementation of promising new research in minority health and disparities research from junior faculty and established investigators looking to refocus their research in this area.

Aim 2: Provide training, career development and mentoring of awardees in minority health research.

Aim 3: Monitor the progress of CEP awardees to develop independent careers and/or new research programs in minority health and assess effectiveness of the CEP itself.